高级检索
当前位置: 首页 > 详情页

Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [2]Sun Yat Sen Univ, Dept Radiotherapy, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [3]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China [4]Hainan Med Coll, Affiliated Hosp, Dept Hematol Oncol, Haikou, Hainan, Peoples R China
出处:
ISSN:

关键词: NON-HODGKIN-LYMPHOMA C VIRUS LAMIVUDINE PROPHYLAXIS L-ASPARAGINASE NASAL-TYPE COMBINATION CHEMOTHERAPY REACTIVATION METAANALYSIS GEMCITABINE

摘要:
Studies have shown that hepatitis B virus (HBV) infection may play an important role in the lymphomagenesis of lymphoma, but no studies regarding the relationship between HBV infection and extranodal natural killer/T cell lymphoma (ENKTL) have been reported previously. One hundred and seven patients diagnosed with ENKTL were retrospectively reviewed. The hepatitis B surface antigen (HBsAg)-positive rate was 13.1%, and no significant correlation existed between HBV infection and clinical characteristics (p > 0.05). No significant difference existed in complete remission rate between HBsAg-positive and -negative groups (42.9% vs. 44.1%, p = 1.000). In a multivariate Cox regression model that included international prognostic index (IPI) score, induction chemotherapy regimen and HBsAg status, all these variables were independent prognostic factors for overall survival (OS) and progression-free survival (PFS) (p < 0.05). In conclusion, the HBsAg-positive rate in ENKTL was similar to that of the normal population in a high HBV endemic area, and HBsAg-positive status was an independent prognostic factor for OS and PFS.

基金:

基金编号: 12ykpy54 04190101

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 4 区 血液学 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 血液学 4 区 肿瘤学
JCR分区:
出版当年[2013]版:
Q2 HEMATOLOGY Q3 ONCOLOGY
最新[2024]版:
Q3 HEMATOLOGY Q3 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [3]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
通讯作者:
通讯机构: [*1]Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Hematol Oncol, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma [2]Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma [3]Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma [4]CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis [5]儿童头颈部非霍奇金淋巴瘤21例临床分析 [6]High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients [7]A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma [8]Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy [9]Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy [10]Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up

资源点击量:28508 今日访问量:0 总访问量:1584 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)